U.S. Markets open in 1 hr 39 mins

Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)--

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that Dr. Bassam Damaj, President & Chief Executive Officer, and Ryan Selhorn, Vice President, Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th Annual Global Investment Conference, on Thursday, September 6, 2018. They will present an update on the Company’s growing revenues, the launch of new products, its path to profitability and its other business plans.

Dr. Damaj and Mr. Selhorn will be meeting with members of the investment community during one-on-one meetings at the conference as well. The corporate presentation will be available for download on the Innovus Pharma web site (www.innovuspharma.com).

About Conference Presentation Time

Event: H.C. Wainwright 20th Annual Global Investment Conference

Date: Thursday, September 6, 2018

Time: 10:25 AM-10:50 AM EDT

Location: St. Regis New York at 2 E 55th St., New York, NY 10022

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly; (b) commercial partners to primary care physicians, urologists, gynecologists and therapists; and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; www.diabasens.com; and www.xyralid.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues its products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180829005173/en/